A new multistage vaccine is ready for clinical development. An article at Nature Medicine shows the preclinical data of the multiantigenic vaccine H56. By combining antigens related to the acute and the latent phase of Mycobacterium tuberculosis. This vaccine is expected to be more protective than the actual vaccine BCG.
These have been the conclusions obtained by an International Consortium funded by the Bill and Melinda Gates Foundation, the Grand Challenge #12, in which the UTE has played a relevant role by demonstrating the activity of the vaccine against the latent phase of the bacilli. The long lasting activity of the UTE for knowing better the Latent Tuberculosis Infection has then a new positive outcome.
If you want to read the article press here: AagardNatMed_2011_H56